CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

CNS Pharmaceuticals (NASDAQ:CNSP) announced its participation in the Virtual Investor “Why Now” on-demand conference held on August 27, 2026.

Rhea-AI Summary

CNS Pharmaceuticals (NASDAQ:CNSP) announced its participation in the Virtual Investor “Why Now” on-demand conference held on August 27, 2026. President and CEO Rami Levin discussed the company’s strategic transformation, highlighting its newly assembled executive leadership team, enhanced financial position following recent financing, and disciplined approach to evaluating differentiated assets.

The company stated that these initiatives aim to support long-term growth and value creation as it advances the next phase of its strategy. The conference video webcast is now available for on-demand viewing. JTC Team and Virtual Investor Co. are described as paid investor relations and corporate communications consultants to CNS Pharmaceuticals.

Argus Aug 27 session 1 alert

+1.42% close to close 3.43K volume Open Argus

Details

News Market Reaction – CNSP

$8.40M Market Cap

On Aug 27, the day this news came out, CNSP closed 1.42% above the previous close.

Data tracked by StockTitan Argus for the Aug 27 session.

Key Figures

Announcement date: August 27, 2026

Announcement date

August 27, 2026

Conference participation announcement

Historical Context

5 past events · Latest: Aug 12

5 events

1. Aug 12

   Second-quarter earnings

   24h Move

   -8.9%

   Reported quarterly net loss while highlighting stronger cash position after financing.

2. Jun 08

   Investor segment

   24h Move

   -2.2%

   Discussed recent financing and strategic reset in a Virtual Investor segment.

3. May 14

   First-quarter earnings

   24h Move

   -9.2%

   Reported higher year-over-year expenses and net loss alongside financing plans.

4. May 04

   Private placement

   24h Move

   +239.2%

   Announced oversubscribed financing with $22.5 million in expected gross proceeds.

5. Mar 11

   Strategy pivot

   24h Move

   -11.6%

   Announced acquisition-focused pipeline strategy for differentiated neurology and oncology assets with defined milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Video webcast now available here

HOUSTON, TX / ACCESS Newswire / August 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor "Why Now" on-demand conference.

Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's strategic transformation that is being built on the strength of its newly assembled executive leadership team, enhanced financial position following its recent financing, and disciplined approach to evaluating differentiated assets. Mr. Levin emphasized the Company's efforts to generate long-term growth and value creation as it executes the next phase of its strategy.

The video webcast is now accessible for on-demand viewing here.

JTC Team and Virtual Investor Co. are paid consultants to CNS Pharmaceuticals, Inc. JTC Team and Virtual Investor Co. are investor relations and corporate communications firms. Any content included in this release shall not be construed as an offer to purchase securities of CNS Pharmaceuticals, Inc. Interested parties are responsible for conducting their own due diligence and are encouraged to review the Company's website and the SEC website for the latest information and filings on the Company.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.

For more information, please visit www.CNSPharma.com, and connect with the Company on X and LinkedIn.

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the anticipated use of proceeds from the Company's recent $22.5 million financing discussed in the video webcast, the Company's ability to identify and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and key milestones related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

CONTACTS:

Investor Relations Contact

JTC Team, LLC
Jenene Thomas
908.824.0775
CNSP@jtcir.com

Business Development Contact

CNS Pharmaceuticals, Inc.
Dylan Wenke, Chief Business Officer
dwenke@cnspharma.com

SOURCE: CNS Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CNS Pharmaceuticals (NASDAQ:CNSP) announce on August 27, 2026 regarding the Virtual Investor "Why Now" conference?

CNS Pharmaceuticals announced that it participated in the Virtual Investor “Why Now” on-demand conference. According to CNS Pharmaceuticals, President and CEO Rami Levin used the event to outline the company’s strategic transformation, leadership changes, improved financial position after recent financing, and its disciplined asset-evaluation approach.

Where can investors watch the CNS Pharmaceuticals (CNSP) Virtual Investor "Why Now" conference webcast?

The CNS Pharmaceuticals Virtual Investor “Why Now” conference webcast is available for on-demand viewing online. According to CNS Pharmaceuticals, the video webcast can be accessed via the provided conference link, allowing investors to review management’s discussion of strategy, leadership, financial position, and asset-evaluation priorities at their convenience.

What strategic themes did CNS Pharmaceuticals (CNSP) highlight during the Virtual Investor "Why Now" conference?

CNS Pharmaceuticals highlighted strategic transformation, a new executive leadership team, and an enhanced financial position. According to CNS Pharmaceuticals, management also emphasized a disciplined approach to evaluating differentiated therapeutic assets and a focus on generating long-term growth and value as it executes the next phase of its corporate strategy.

How did recent financing affect CNS Pharmaceuticals (NASDAQ:CNSP) as discussed at the Virtual Investor conference?

Recent financing was described as strengthening CNS Pharmaceuticals’ financial position. According to CNS Pharmaceuticals, this enhanced financial position supports the company’s strategic transformation, enabling a more disciplined evaluation of differentiated assets and helping underpin its efforts to pursue long-term growth and value creation for patients and shareholders.

What is the business focus of CNS Pharmaceuticals (CNSP) mentioned alongside the Virtual Investor "Why Now" event?

CNS Pharmaceuticals focuses on developing innovative therapies for serious diseases with significant unmet medical needs. According to CNS Pharmaceuticals, the company aims to build a differentiated portfolio of high-value therapeutic assets and is committed to advancing novel treatments that may improve patient outcomes and create long-term shareholder value.

Are JTC Team and Virtual Investor Co. independent of CNS Pharmaceuticals (CNSP) in the August 27, 2026 announcement?

JTC Team and Virtual Investor Co. are identified as paid consultants to CNS Pharmaceuticals. According to CNS Pharmaceuticals, these firms provide investor relations and corporate communications services, and any content in the announcement is not an offer to purchase CNS Pharmaceuticals securities and requires independent investor due diligence.